March 3, 2006 -- Celgene won priority review for Revlimid as a therapy for relapsed/refractory multiple myeloma, giving it a review date of June 30, 2006; SFBC International said it would postpone release of its Q4 financial report until March 8; Medicis Pharma said the FDA approved Vanos, its psoriasis drug, for additional indications; Covalent Group, a contract research company, will buy a Finnish CRO called Remedium Oy for $20 million; Kosan announced a restructuring that will cut one-third of its employees, a total of 39 positions; and Cubist and the FDA have published the relevant documents for the FDA advisory panel meeting on additional indications for Cubicin. The Centient Biotech 200™ was off 34 points at 4022.39, a decline of .84%. More details...
